You are here » Home » Companies » Company Overview » Dai-ichi Karkaria Ltd

Dai-ichi Karkaria Ltd.

BSE: 526821 Sector: Industrials
NSE: DAICHIKARK ISIN Code: INE928C01010
BSE LIVE 15:58 | 20 Sep 410.85 3.40
(0.83%)
OPEN

415.00

HIGH

422.95

LOW

405.20

NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 415.00
PREVIOUS CLOSE 407.45
VOLUME 2238
52-Week high 605.00
52-Week low 381.10
P/E 19.62
Mkt Cap.(Rs cr) 306
Buy Price 0.00
Buy Qty 0.00
Sell Price 410.85
Sell Qty 10.00
OPEN 415.00
CLOSE 407.45
VOLUME 2238
52-Week high 605.00
52-Week low 381.10
P/E 19.62
Mkt Cap.(Rs cr) 306
Buy Price 0.00
Buy Qty 0.00
Sell Price 410.85
Sell Qty 10.00

Dai-ichi Karkaria Ltd. (DAICHIKARK) - Company History

Dai Ichi Karkaria (DIK), manufactures speciality chemicals has a tie-up with Matsumoto to manufacture spin finishes, which are used for imparting lubrication and anti-static properties to textile filaments and yarns. It is now expanding its production capacity from 750 tpa to 3000 tpa. DIK had set up a unit to manufacture certain bulk drugs omeprazole, menadione and calcium pentothenate, the last two will be manufactured in India for the first time. DIK is also setting up a unit to manufacture 600 tpa of polyacrylamide-based flocculents which are used for solid-liquid separation. The expansion cum Diversification plan for High Molecular Weight Flocculants Project at Kurkumbh has been successfully completed. Company had joint venture with project consultant for effluent treatment plants for increasing business. Company Bulk Drugs & Fine Chemical Projects for patented molecule processes were developed and were scaled up to commercial level by March-99. Company plans to start development of three new products in the pilot facility which is being upgraded presently to meet strict cGMP condition. Company also negotiating with foreign customer for product specific tie-ups in future. Company Spin fishes continue to do well & POY DTY finish has been accepted in the market & company hopes to get orders from leading synthetic fibre manufacturers. During the year 1999-2000, the company's successfully introduced eight new products in therapeutic areas of cardiovascular, antihistaminics, analgesics, anxiolytic, antidepressant and anticonsulgants. The diversification programme which was taken up by the company is focusing in the three major areas are ETP,paper and Alumina industry.